Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. is a global healthcare company headquartered in Chiyoda, Tokyo, Japan. Established on August 10, 1964, the company operates under the corporate philosophy of "Otsuka-people creating new products for better health worldwide." Its core business encompasses the research, development, manufacturing, sale, export, and import of pharmaceuticals, clinical testing equipment, medical devices, food products, and cosmetics.

The company's operations are primarily divided into two pillars: a pharmaceutical business focused on addressing unmet medical needs and a nutraceutical business dedicated to maintaining everyday health. In the pharmaceutical sector, Otsuka is a leader in challenging therapeutic areas such as Central Nervous System (CNS) disorders (including mental health), nephrology (kidney health), oncology, and cardiovascular health. Key products include Abilify (aripiprazole) and Rexulti (brexpiprazole) for CNS disorders, and Jynarque (tolvaptan), Samsca (tolvaptan), and Voyxact (sibeprenlimab-szsi) in nephrology.

Under the leadership of President and Representative Director Makoto Inoue, Otsuka Pharmaceutical continues to advance its pipeline and market presence. Recent notable developments include positive Phase 3 VISIONARY Two-Year eGFR Results for VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy, demonstrating its potential to prevent kidney failure and improve kidney function, reported in July 2026. In June 2026, the company announced positive Phase 3b results for Centanafadine in adults with ADHD and comorbid anxiety and completed the acquisition of Transcend Therapeutics to expand its portfolio in psychiatric and neurological fields. Otsuka Pharmaceutical Co., Ltd. is a wholly-owned subsidiary of Otsuka Holdings Co., Ltd., which is publicly traded on the Tokyo Stock Exchange (TSE:4578) and in the U.S. via OTC Markets (OTCMKTS:OTSKY).